SpecialtiesQuestion

Can procalcitonin be used as a marker for endothelial dysfunction emanating from chronic inflammation of obesity?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Do you recommend restarting a GLP-1RA after bariatric surgery if the patient tolerated it before the surgery?

Why is it recommended to switch to a non-oral contraceptive or add a barrier method of contraception for 4 weeks after tirzepatide initiation but not with semaglutide?

In patients with MASLD, would you consider management with off-label metformin, pioglitazone (despite weight gain risk), GLP-1 RA, or simply intensify lifestyle and monitor?

How long do you trial lifestyle therapy before initiating pharmacologic treatment in a patient with BMI 30–35 without diabetes?

In routine practice where repeat biopsy and outcomes data are not available, what longitudinal NIT pattern (e.g., VCTE/ELF ± MRI-PDFF/ALT trajectory) do you consider sufficient to continue semaglutide specifically for MASH, and what trajectory would trigger a “futility” decision to stop or switch despite weight loss?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.